A one day Science Symposium: celebration of 20 years of ExcellGene

July 19, 2022

Share This Post

We at Magellan Biologics & Consulting proudly support our sister Company in the organization of this extraordinary scientific conference!

Get updates

Subscribe To Our Newsletter

More To Explore

A Historic Milestone: Magellan Biologics & Consulting Enters a New Era with ARCHIMED

Magellan Biologics and its sister company ExcellGene have entered a new strategic partnership with ARCHIMED, a global med-tech investment firm Press Release ARCHIMED acquires cell

25 September 2025

A novel drug produced in CHO cells has recently been approved by the FDA

Tislelizumab-jsgr is a PD-1 blocking antibody indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic

29 March 2024

A one day Science Symposium: celebration of 20 years of ExcellGene

Share This Post

Get updates

Subscribe To Our Newsletter

More To Explore

A Historic Milestone: Magellan Biologics & Consulting Enters a New Era with ARCHIMED

A novel drug produced in CHO cells has recently been approved by the FDA

Interested in our products?

Drop us a line and keep in touch

Welcome on board!

Subscribe to our Newsletter
and stay updated!

Get Updates!

If you opt in above we use this information send related content

A one day Science Symposium: celebration of 20 years of ExcellGene

Share This Post

Get updates

Subscribe To Our Newsletter

More To Explore

A Historic Milestone: Magellan Biologics & Consulting Enters a New Era with ARCHIMED

A novel drug produced in CHO cells has recently been approved by the FDA

Interested in our products?

Drop us a line and keep in touch

Welcome on board!

Subscribe to our Newsletter and stay updated!

Get Updates!

If you opt in above we use this information send related content

Subscribe to our Newsletter
and stay updated!